tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
dimethyl fumarate teva
teva gmbh - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 7,5 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 7,5 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 20 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 20 mg
dicloxacillin bluefish hart hylki 250 mg
bluefish pharmaceuticals ab - dicloxacillinum natríum - hart hylki - 250 mg
carvedilol stada tafla 3,125 mg
stada arzneimittel ag - carvedilolum inn - tafla - 3,125 mg
carvedilol stada tafla 6,25 mg
stada arzneimittel ag - carvedilolum inn - tafla - 6,25 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 25 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 25 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 17,5 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 17,5 mg